GSK 6-K 2026 - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	20.727

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	264.587

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Mike Crichton
b)	Position/status	President, International
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	113.059

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial<br>notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	1,789.579

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Nina Mojas
b)	Position/status	President, Global Product Strategy
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	218.712

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Roanne Parry
b)	Position/status	Chief People Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	1.244

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	5,803.725

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	2,990.691

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	2,405.345

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	1,070.064

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	2,273.327

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63<br><br><br>avid<br>Redfe
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	150.689

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Kate Thomson
b)	Position/status	PCA of Philip Thomson (President, Global Affairs)
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.6297	99.710

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-09
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.7550	6

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-13
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.7550	6

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-13
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 July 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.5950	664
			£19.5950	333
			£19.5950	244

d)	Aggregated<br>information
	Aggregated<br>volume Price	1,241<br><br><br>19.5950
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 July 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.5950	533
			£19.5950	621
			£19.5950	482

d)	Aggregated<br>information
	Aggregated<br>volume Price	1,636<br><br><br>19.5950
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 July 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.5950	115
			£19.5950	357
			£19.5950	216

d)	Aggregated<br>information
	Aggregated<br>volume Price	688<br><br><br>19.5950
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br> <br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Increase in notional interest in ADS following the re-investment of<br>dividends paid to shareholders on 9 July 2026 on ADSs held in the<br>Company's Deferred Annual Bonus Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$52.4700	167
			$52.4700	56
			$52.4700	101

d)	Aggregated<br>information
	Aggregated<br>volume Price	324<br><br><br>52.4700
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)

All values are in US Dollars.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 July 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.5950	170
			£19.5950	422
			£19.5950	192

d)	Aggregated<br>information
	Aggregated<br>volume Price	784 <br><br><br>19.5950
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 July 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.5950	178
			£19.5950	282
			£19.5950	509

d)	Aggregated<br>information
	Aggregated<br>volume Price	969<br><br><br>19.5950
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 July 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.5950	123
			£19.5950	284
			£19.5950	171

d)	Aggregated<br>information
	Aggregated<br>volume Price	578<br><br><br>19.5950
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 July 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.5950	162
			£19.5950	440
			£19.5950	265

d)	Aggregated<br>information
	Aggregated<br>volume Price	867<br><br><br>19.5950
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 July 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.5950	247
			£19.5950	542
			£19.5950	226

d)	Aggregated<br>information
	Aggregated<br>volume Price	1,015 <br><br><br>19.5950
e)	Date<br>of the transaction	2026-07-10
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial<br>notification/<br><br><br>amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026 on Ordinary Shares<br>held within an ISA
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.755	18

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-13
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 July 2026 on Ordinary Shares<br>held within an ISA
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£19.755	15

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume Price
e)	Date<br>of the transaction	2026-07-13
f)	Place<br>of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: July<br>14, 2026

	By:/s/ VICTORIA<br>WHYTE<br><br><br>--------------------------

	Victoria Whyte
	Authorised<br>Signatory for and on
	behalf<br>of GSK plc